Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.65 |
| ▸ | NPC1 | O15118 | 9/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.65 |
| ▸ | STAT1 | P42224 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | ALPL | P05186 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9722853 | 0.89 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL5208143 | 0.89 | NPC1 (0.52) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| Bromide SCHEMBL261012 | 0.88 | NPC1 (0.51) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL9722808 | 0.87 | NPC1 (0.55) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL4667327 | 0.86 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL11439414 | 0.85 | CYP2C9 (0.54) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL9722788 | 0.85 | CYP2C9 (0.60) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL9722767 | 0.85 | CYP2C9 (0.53) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL145671 | 0.84 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 | |
| SCHEMBL30189826 | 0.84 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2STAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655225-B2 | Antimycobacterial heterocyclic amides | CRESTONE, INC. (US) | 2023-05-23 | — | — | US | claimed |
| CN-112423746-A | Novel anti-mycobacterial heterocyclic amides | 克莱斯通公司 | 2021-02-26 | — | — | CN | claimed |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | CRESTONE, INC. | 2021-01-07 | — | — | US | claimed |
| EP-3758697-A1 | NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES | Crestone, Inc. (US) | 2021-01-06 | — | — | EP | claimed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-117126578-B | Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof | 中国科学院海洋研究所 | 2025-04-22 | — | — | CN | disclosed |
| US-3971740-A | DYES FOR POLYESTER FIBERS | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
| US-3971771-A | DYES FOR POLYESTERS | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
| US-3964862-A | Process for dyeing and printing textile materials of synthetic organic fibers | CIBA-GEIGY AG (CH) | 1976-06-22 | — | — | US | disclosed |
| US-3954398-A | Polyester fibers dyed with a disazo disperse dyestuff | CIBA-GEIGY AG (CH) | 1976-05-04 | — | — | US | disclosed |
| US-3945991-A | Heterocyclic azo compounds containing a quaternated hydrazide group | CIBA-GEIGY AG (CH) | 1976-03-23 | — | — | US | disclosed |
| US-3945989-A | Fluoro triazine containing water insoluble azo dyestuff | CIBA-GEIGY AG (CH) | 1976-03-23 | — | — | US | disclosed |
| US-3933786-A | Heterocyclic-azo-phenyl compounds containing a styrl group | CIBA-GEIGY AG (CH) | 1976-01-20 | — | — | US | disclosed |
| US-3931145-A | POLYESTER | GAF CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | RAB9A 2519/4885NPC1 2376/4885SMN1; SMN2 3226/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | RAB9A 2519/4885NPC1 2376/4885SMN1; SMN2 3226/4885 |
| US-11655225-B2 | Antimycobacterial heterocyclic amides | AADAC, CPS1, NAT1 | RAB9A 1973/4885NPC1 1093/4885SMN1; SMN2 4466/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | RAB9A 2519/4885NPC1 2376/4885SMN1; SMN2 3226/4885 |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | AADAC, CPS1, ACAT1 | RAB9A 1886/4885NPC1 1474/4885SMN1; SMN2 4672/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | RAB9A 3850/4885NPC1 930/4885SMN1; SMN2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.